ASCO GI Conference Coverage
Filter News By:
Featured News
View all
More News
(Five Prime) Dec 9, 2020 - Detailed results of the Phase 2 FIGHT trial have been accepted for late breaker presentation during the Esophageal and Gastric cancer oral abstract session on January 15, 2021.
(Medscape Medical News) Feb 18, 2020 - Should the age be lowered in view of the mounting reports of an increase in CRC in younger adults? Experts argued both for and against the move here at the 2020 Gastrointestinal Cancers Symposium.
(Medscape Medical News) Jan 27, 2020 - For patients with unresectable hepatocellular carcinoma (HCC), the combination of atezolizumab (Tecentriq, Genentech) plus bevacizumab (Avastin, Genentech) has already shown better efficacy than...
(MedPage Today) Jan 25, 2020 - Only the two-drug combination of encorafenib (Braftovi) plus cetuximab (Erbitux) will undergo regulatory review by the FDA for metastatic BRAF-mutant colorectal cancer at this time, a researcher reported...
(MedPage Today) Jan 24, 2020 - So-called switch maintenance with an immune checkpoint inhibitor failed to improve overall survival (OS) in treatment-naive HER2-negative advanced gastric or gastroesophageal junction cancer, results of a...
(MedPage Today) Jan 26, 2020 - Resection of the primary tumor ahead of chemotherapy yielded no survival benefit for newly diagnosed metastatic colorectal cancer (CRC) patients with asymptomatic primaries, a randomized trial from Japan...
(Medscape Medical News) Jan 24, 2020 - Escalating the dose of radiation therapy does not appear to improve outcomes for patients with esophageal cancer who are receiving definitive chemoradiation, according to new findings.
(Taiho Oncology) Jan 25, 2020 - Taiho Oncology, Inc. announced today the presentation of a pooled analysis for hematologic adverse events of the global Phase III TAGS and RECOURSE trials evaluating LONSURF® (trifluridine and tipiracil) in...
(Yahoo! News) Jan 27, 2020 - All patients showed tumor regression by radiographic scan at 8 weeks and confirmation by further tumor shrinkage at 16 weeks; clinical benefit achieved in 100% (n=5) of patients.
(Yahoo! Finance) Jan 25, 2020 - NantHealth, Inc. today announced results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 GI.

OBR Tweets

Apr 16
Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?…

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat…

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a…

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL…

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib